Atossa Genetics completes enrollment in topical arm of endoxifen phase 1 study
Atossa Genetics announced that it completed enrollment in the topical arm of its Phase 1 dose escalation study of Atossa's proprietary Endoxifen. Endoxifen is an active metabolite of the FDA-approved drug tamoxifen, which is used to treat breast cancer and for breast cancer prevention. May 19, 2017